Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer
β Scribed by Masaru Izuo; Yuichi Iino; Keiichi Endo
- Publisher
- Springer US
- Year
- 1981
- Tongue
- English
- Weight
- 510 KB
- Volume
- 1
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effects of oral MPA, 300 mg t.i.d., on adrenal function in postmenopausal patients with disseminated breast cancer were evaluated. The levels of serum cortisol, ACTH, androstenedione, DHEA-S, LH, FSH, GH, and prolactin in 22 patients receiving MPA were compared with those in another group of 28
Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high
Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is